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ABSTRACT
The development of strongly predictive validated
biomarkers is essential for the field of immuno-oncology
(IO) to advance. The highly complex, multifactorial data
sets required to develop these biomarkers necessitate
effective, responsible data-sharing efforts in order to
maximize the scientific knowledge and utility gained
from their collection. While the sharing of clinical- and
safety-related trial data has already been streamlined to a
large extent, the sharing of biomarker-aimed clinical trial
derived data and data sets has been met with a number of
hurdles that have impaired the progression of biomarkers
from hypothesis to clinical use. These hurdles include
technical challenges associated with the infrastructure,
technology, workforce, and sustainability required for
clinical biomarker data sharing. To provide guidance and
assist in the navigation of these challenges, the Society for
Immunotherapy of Cancer (SITC) Biomarkers Committee
convened to outline the challenges that researchers
currently face, both at the conceptual level (Volume I)
and at the technical level (Volume II). The committee also
suggests possible solutions to these problems in the form
of professional standards and harmonized requirements
for data sharing, assisting in continued progress toward
effective, clinically relevant biomarkers in the IO setting.

INTRODUCTION: PRACTICAL CHALLENGES IN
DATA SHARING FOR CLINICAL BIOMARKER
DEVELOPMENT
Data sharing today enables the new science
of tomorrow. It is increasingly evident that
studies analyzing previously published data
can achieve new discoveries, often having
as much impact as the original projects,
and can greatly improve medical research
and benefit all stakeholders. While the
companion volume to this paper, ‘Society
for Immunotherapy of Cancer clinical and
biomarkers data-sharing resource document:
Volume I—conceptual challenges’, provides

an overview of the surrounding framework
and proposed activities of stakeholders for
responsible and successful data sharing, this
practical challenges volume will examine and
address the more procedural details of the
current hurdles to data sharing.1 Here, we
dissect those hurdles down to basic approachable elements that must be addressed to
encourage better data-sharing strategies and
compliance. Additionally, we put forward
timely recommendations and methodological guidelines that will also remain flexible
enough for adaptation to both current and
future landscapes of data sharing.
For responsible data sharing to become
the new norm, and to engender a lasting
paradigm shift, it must first be embraced by
all stakeholders and influencers. The importance of careful planning and execution
of data-
sharing protocols must be placed
alongside any new clinical hypothesis tested.
A broad range of sensible changes can be
made to the current landscape of medical
science in order to encourage the acceptance of data-sharing initiatives as a necessary component of scientific collaboration.
In order to discuss important considerations regarding data-sharing initiatives, the
Society for Immunotherapy of Cancer (SITC)
Biomarkers Committee formed the Clinical
and Biomarkers Data Sharing Subcommittee,
which developed two manuscripts, Volumes
I and II, respectively, addressing conceptual
and practical challenges to data sharing.
This manuscript (Volume II) is divided into
four sections, each addressing a specific group
of practical challenges in data sharing. In the
Infrastructure challenges section, we describe
considerations for contracting intellectual
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property (IP) and biospecimen collection associated with
multicenter network infrastructure planning, considerations for the continuous validation of evolving platforms and technologies, and proposals for cloud-based
computing methods that maintain required constants in
communication. In the Technological challenges section,
we describe popular data platforms that are standardizable, discoverable, searchable, and interoperable, as well
as how these platforms require the development and
adoption of common protocols to deliver common data
elements for meaningful computation across disparate
data sets. In the Workforce challenges section, we outline
the expected knowledge and skills required of expert
personnel trained to execute the design, management,
technical, and operational aspects of data sharing. Finally,
in the Sustainability challenges section, we address how
the undervalued costs of data organization and sharing
are borne by a small set of stakeholders and the need
for these costs to be equitably redistributed across benefitting parties, in addition to how universities, research
foundations, and professional societies can better foster
and support data-sharing sustainability.
INFRASTRUCTURE CHALLENGES
With the ever-growing sophistication and cost of correlative science for immunotherapy clinical trials, many
stakeholders have realized that the future lies in large
collaborative efforts that make the best use of the
breadth and depth of information generated from high-
dimensional and single-
cell technologies. These stakeholders include major academic centers, federal funding
sources, philanthropic foundations/societies, and pharmaceutical/biotech companies. Stand-
alone federal
funding for laboratories is increasingly being phased
out in favor of multi-principal investigator (PI) applications, with preference for those involving multiple collaborating institutions.2 3 In addition, entities such as the
Parker Institute for Cancer Immunotherapy, the Multiple
Myeloma Research Foundation, the Foundation for the
National Institutes of Health, and some pharmaceutical
companies have engaged funding to create Networks
of Excellence that bring together multiple academic
centers with top expertise for collaborative streamlining
of their technical and analytical pipelines. However, the
infrastructure required to execute these goals needs to
evolve accordingly, from virtual collaboration to the physical creation of networks with coordinated, synchronous
efforts.
A recently implemented example of multicenter infrastructure for biomarker discovery is the Cancer Immune
Monitoring and Analysis Centers-
Cancer Immunologic
Data Commons (CIMAC-CIDC) Network, funded by the
National Cancer Institute’s (NCI’s) U24 Cancer Moonshot Initiative.4 This grant of more than US$50 million
led to the establishment of four CIMACs, which are
tasked with performing a complex and comprehensive
set of assays using biospecimens collected from patients
2

undergoing immunotherapy in clinical trials under the
NCI’s Cancer Therapy Evaluation Program cooperative
groups. The goal of this initiative is to generate rich integrated data sets that correlate treatment mechanisms
(ie, multi-omic biomarkers) with clinical outcomes (ie,
response to treatments, progression, and overall survival).
CIDCs will maintain and centralize these integrated data
sets, leading to the eventual creation of a mineable public
database of well-validated, harmonized, and integrated
data, with the hope that better predictive biomarkers
might be discovered from these data. Establishing this
pipeline for the generation, analysis, and centralized
storage of this integrated data requires an unprecedented
framework of infrastructure, which is organized from a
series of working groups with an overseeing committee.
This infrastructure enables the monitoring of all steps
in the process, from trial selection and sample management, to data collection, analysis, and dissemination. This
project has identified a number of obstacles met during
the creation of successful data-
sharing infrastructure,
which are discussed below.
Contracts, IP, and ethics
Establishing contracts between institutions—including
pharma/biotech companies, biobanks, and trial PIs—
represents one of the principle roadblocks to data
sharing. Specifically, questions arise around putting in
place contracts generated only by participating centers
versus the use of master agreements covering all institutions and partners in general terms, and how to distribute
IP and publication deliverables from discoveries made.
Different methods by which joint IP can be apportioned
between contributing parties have been used, with the
most straightforward method being for the involved
parties to agree that any joint IP created as a result of
the collaboration is jointly owned by the parties. However,
this structure only works if all parties are willing to allow
the unrestricted use of the joint IP by one another. Often,
due to the parties’ business or technical concerns, there
might need to be restrictions on one or both party’s use
of joint IP, which could be addressed in different ways.
For example, all of the IP rights could be assigned to one
of the parties, which then would grant a license, limited
as dictated by business or technical concerns, to the other
party. Alternatively, both parties can be considered joint
owners of all the joint IP, with each party agreeing to
certain restrictive conditions on their use or disclosure
of it. Special considerations exist when one of the parties,
often an educational institution, receives government
funding, since in that case the government may have
rights to use IP (and possibly any underlying contributed IP) created as a result of government funding. In
that case, as part of the agreement, the IP created with
government funding should be available without overly
burdensome restrictions, taking into account any requirements that apply to particular IP because of government
funding.
Cesano A, et al. J Immunother Cancer 2020;8:e001472. doi:10.1136/jitc-2020-001472
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If the network agrees on collaborative terms, implying
shared authorship and IP rights, some rules may conflict
with existing bylaws of established cooperative groups.
Even if and when a common language of defined terms
is finally agreed to by all parties, amendments to existing
clinical protocols and consent forms need to be considered to ensure that samples can be shared in accordance
with local institutional review boards (IRBs). One recommendation is to engage legal and contractual teams at
each site together, rather than individually, to facilitate
mutual agreements. As this includes contract offices, IP
offices, material transfer agreements, IRBs, exchanges
between PIs, lab testing sites, and biobanks, the networks
of legal interactions between these different facilitators
and stakeholders must be planned as early in the development process as possible. In addition, the language
used in clinical protocols to perform correlative assays
and to share resulting biospecimens for a study should
allow flexibility in assays performed, and include provisions in informed consent documents for the future use
of samples in later experiments or analyses, including
testing of novel biomarkers.
Specimen collection
A network may depend on central biobanks or on local
site processing, each having their own rules for sample
collection, processing, storage, and sharing. Since an
important step in biomarker validation is the evaluation
of preanalytical factors that may affect assay performance
(including specimen collection, handling, and processing
variables), standard operating procedures for controlling
specific biomarker development steps are essential and,
to this effect, guidelines have been recently developed
by CIMACs.5 6 Banks and networks receiving specimens
need to coordinate their laboratory information management systems and ensure end-
to-
end quality assurance, with 24/7 monitoring of storage conditions and
temperature-controlled shipping containers. Important
details to consider include codes used for the original
specimens versus those used by the network, as well as
the development of common vocabulary dictionaries for
metadata. The latter is particularly important since metadata summarizes basic information about the data, thus
making finding and working with particular instances
of data easier. In addition, establishment of priority on
sample use by individual institutions versus the network
should be explicitly and clearly defined. The recommendations for all of these variables are summarized in an
umbrella collection protocol by CIMAC, assembled by
experts in assays and biobanking, and which will help
investigators properly plan in advance.7
Some novel assays, such as single-cell high-dimensional
immune profiling, tend to be dependent on high-quality
materials (eg, biospecimens), typically extracted from
fresh patient tissues.8 9 Bringing surgeons, endoscopists,
interventional radiologists, pathologists, and scientists
together is critical to ensure timely collection of samples
with minimal time to processing. Education and interest/
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involvement from all parties is key, and identifying such
partners is vital to the success of a collaboration. However,
logistical issues must also be considered, such as the need
for runners (ie, biobanking technicians) and the timely
delivery of specimens from operating rooms to analytical
laboratories.
Equipment and conduct of research
A major reason for performing collaborative research in
multiple centers is the high cost of state-of-the-art equipment. Often, these networks may choose to centralize
some assays to make them more cost-effective and reduce
the need to standardize protocols across different labs.
However, the throughput of high-
dimensional multi-
parametric technologies is often limiting, and most
networks will need to have redundancy (eg, standards
and controls) in place, to ensure that a consensus can be
reached in how to interpret data generated from different
experiments at different sites measuring similar metrics.
At the heart of multi-center science lies the harmonization of assays and platforms, ensuring that results
can ultimately be compared. The CIMACs have spent
the past 2 years benchmarking their respective assays in
serial rounds of proficiency testing for multiplex immunohistochemistry (IHC), whole exome sequencing, and
RNA sequencing (RNA-
seq), among other assays.5 6 A
particular challenge stems from differences in platforms
at all levels, from antibody clones and reagents used to
machines and interpretation algorithms. Streamlining
these technologies as much as possible is helpful, despite
each site typically already having optimized protocols in
place that are difficult to modify or replace.
Although efforts in protocol standardization are critical
and should lead to vast improvements in workflows, it is
also important to align expectations and to understand
the limitations of harmonizing assays, especially since not
everything can be tested at once. The success and details
of these harmonization efforts will soon be reported, and
recommendations on best practices will also be provided.6
To ensure their relevance, assay comparisons for standardization cannot be a ‘one-and-done’ event, and they
will, in fact, need to be continuously validated and reassessed during the process of such research.
Progress in any collaboration requires constant communication, through the organization of regular conference
calls and presentations. These can also, however, quickly
devolve into time sinks, especially during troubleshooting
phases or real-time analysis of data. Despite expectations
that these networks should be optimized for the continuous generation of data, another important priority is to
continue to allow science to come first, which sometimes
means that extra time is needed to ensure the generation of top-quality data, rather than adhering to a rigid
schedule. An equally important recommendation is to
allow assays to evolve and to improve from study to study,
which is critical despite the temptation to lock them in at
the same technical state for greater reproducibility. When
technical improvements are introduced to keep up with
3
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the cutting edge of research, provisions for bridging and
validation work should be made to guarantee that older
data also remain useful and comparable.
Aside from machines used for assays, computational
and storage infrastructure for data storage, analysis, and
sharing likely represents the biggest technology investment required for effective data sharing. Leasing space on
cloud-based servers versus local servers needs to be carefully considered, as communications or exchange between
them may be challenging. However, cloud computing
may also provide new opportunities for novel research,
since it can allow studies to be performed at larger scales,
using data shared and integrated from multiple sources.10
These benefits should be weighed against the possibility
of risks associated with cloud computing, especially issues
with data security and the need to consider the rights of
research participants. In order to enable large-scale analyses and computing while maintaining patient privacy,
Molnár-Gábor et al advocate a ‘middle-ground’ solution
of federated or hybrid clouds, allowing large-scale cloud
computing while restricting data access to approved individuals and institutions.10 The utility of ‘model to data’type platforms also includes proper facilities for data
storage, advanced data management, and analysis, and
these platforms are poised to address a majority of infrastructure, ethical, technological, and sustainability issues
associated with biomarker and clinical data sharing,
without the need to modify current ethical and legal
frameworks on the usage of clinical data.11
TECHNOLOGICAL CHALLENGES
The goal of data sharing is to provide transparency on
how shared data sets were generated, and to reliably share
comparable cross-
study data, enabling increased statistical power for the identification of biomarkers that are
associated with clinical benefit from the treatment being
investigated. While the former enables reproducibility of
data and comparison with similarly designed future trial
outcomes, the limited availability of patient-derived trial
samples emphasizes the need to plan for comparable
data generation prospectively from a technology platform
viewpoint. In this context, the current technology platforms used for analysis and robust biomarker generation
represent an inherent challenge to providing comparable
data sets at the single biomarker level, and even greater
challenges to meeting the current and ever-
growing
demand for multiplex analysis of patient-derived samples
for observations of the intrinsic and varied complexity of
tumor-immunobiology.
With the goal of increasing the comparability of patient-
derived biomarker data originating from the same or
similar technology platforms, for any individual technology, in-depth knowledge on the sensitivity, specificity,
stability (including positive and negative controls used),
the acquisition platform, and the analysis algorithm is
essential. In addition, planning on the format of data
set outputs needs to be considered well in advance, early
4

during the trial design process. Data set formats must
be designed to be compatible with those emerging from
similar studies to avoid the need for later conversion, which
may not be financially feasible or even altogether technically possible. Currently, a number of efforts to achieve
efficient data comparison are in progress, including individual as well as joint retrospective bridging studies, in
addition to attempts at the development of standardized
harmonization protocols for leading technology-derived
assays. Below, examples of such efforts are discussed in
further detail.
Variabilities of immune checkpoint expression status across
different immunohistochemistry platforms
One of the most prominent and timely examples in
immuno-oncology (IO) that also illustrates the critical
need to harmonize platform-specific technologies is the
group of antibody-
based therapies called checkpoint
inhibitors targeting the programmed cell death protein-1
(PD-1)/programmed death-
ligand 1 (PD-
L1) axis.
Currently, there are six different checkpoint inhibitors
approved by the US Food and Drug Administration (FDA)
that have demonstrated a positive association between
clinical outcome and the expression of the PD-L1 protein
within the tumor microenvironment.12 13 In patients with
non-small cell lung cancer, observation of PD-L1 expression on tumor cells (using IHC technology) has been
associated with clinical benefit, and has thus resulted in
the development of companion/complementary diagnostic (CDx) tests designed to evaluate the PD-L1 status
of each patient prior to treatment with anti-PD-1 or anti-
PD-L1 checkpoint inhibitors.14 However, multiple proprietary PD-L1 IHC assays were developed using different
primary antibody clones, IHC platforms, protocols,
sensitivities, and scoring methods or algorithms. Despite
using the same overall technology and target (PD-
L1
protein expression) the different permutations across
individual assays has led to distinct staining properties
and patterning for each, raising concerns about direct
comparability and interchangeability of derived findings
and data sets.15 As a result, two different waves of supplemental bridging studies conducted in a precompetitive
setting using both samples from clinical trials (Blueprint
Phase I Project16) and from real-world settings (Blueprint
Phase II Project17) have been performed. Both of these
studies concluded that, with the exception of one assay,
the different assays and antibody clones used showed
comparable results for PD-L1 expression on tumor cells
(although with some differences in numbers of positive
cells detected per clone used), but showed rather poor
concordance for PD-L1 expression scoring on immune
cells.16 17
While IHC remains a highly practical and cost-effective
diagnostic and prognostic method, this single-
marker
method cannot tell the whole story of the complex
immune microenvironment. Emerging multiplex IHC
and immunofluorescence technologies are promising in
the field of cancer immunotherapy. Unlike conventional
Cesano A, et al. J Immunother Cancer 2020;8:e001472. doi:10.1136/jitc-2020-001472
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IHC, which only allows the labeling of one single marker
in a tissue sample, multiplex IHC is able to detect multiple
markers from a single tissue sample while providing
comprehensive information about the cell composition
and spatial arrangement. The demand for multiplex
IHC technologies that output standardized data from
harmonized protocols will likely increase as it is further
demonstrated that this methodology has the potential to
characterize mechanisms of tumor resistance and escape
in patients.18
Single-cell RNA-seq sample preparation and technologies to
manage complex and difficult-to-harmonize data sets
In line with the increased demand for multiplexing, RNA-
seq technologies have emerged as a useful tool to address
complex, multi-pathway tumor-immune regulation mechanisms, and as a complement to IHC-based protein detection data sets. Beyond the already information-
dense
data sets generated from regular bulk RNA-seq methods,
the advent of single-cell technology (scRNA-seq) offers
tremendous opportunity toward greatly increasing resolution in detection of the full gamut of immune cell
subtypes and simultaneous characterization of their
heterogeneous functional profiles. The data sets associated with scRNA-seq technologies have the potential
to be significantly larger than previous RNA-
seq technologies. There are technological challenges presented
by the many current platforms available for scRNA-seq,
with a number of factors impacting sensitivity and operational applicability.19 For example, the selection of the
initial protocol for transcribing mRNA into cDNA (eg,
full-length sequencing vs expressed sequence tag (EST)
sequencing) results in differing sensitivities for less abundant transcripts.19 In addition, the resolution of scRNA-seq
results can be impacted by different cell sorting methods
such as fluorescence-
activated cell sorting or droplet-
based microfluidics, and by the number of cells acquired,
often varying from sample to sample, and between individual patients.20–25
For cellular subtypes of very low abundance (eg,
dendritic cells in peripheral blood), a presorting enrichment step may be required to characterize subpopulations of interest. However, once data sets are generated
for sharing from these different platforms in, for instance,
clinical trials demonstrating the pharmacodynamics of
a given treatment or for identification of response via
predictive biomarkers, bridging studies comparing them
will certainly be required to assess the reproducibility
and feasibility of harmonization of such data sets. Recent
advances in the field have demonstrated the feasibility
of integrating data sets gathered from scRNA-seq with,
for example, data from single-cell assays for transposase-
accessible chromatin sequencing (scATAC-seq) and with
data from in situ gene expression assays.26 The expected
difficulties in integrating massive numbers of data points
derived from multiple scRNA-
seq studies require that
data sharing must be considered early in the study design
process.
Cesano A, et al. J Immunother Cancer 2020;8:e001472. doi:10.1136/jitc-2020-001472

Tumor mutational burden assay standardization
Another important and currently emerging theme in
predictive biomarkers for IO CDx development is the
genomic assessment of tumor mutational burden (TMB).
TMB represents both a surrogate prognostic marker and a
predictive marker for the presence of tumor neo-antigens
in cancer immunotherapies across multiple cancer types.27
On June 16, 2020, the FDA granted accelerated approval
to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high
(TMB-H) solid tumors, defined as those harboring ≥10
mutations/megabase as determined by an FDA-approved
test (ie, the FoundationOne CDx test), who progressed
following prior treatment and who have no alternative
treatment options.28 The direct measurement of tumor
peptide antigens via methods such as mass spectrometry,
and the ability to load these peptides onto major histocompatibility complex (MHC) molecules is not yet suitable for routine clinical application. However, in current
clinical trials, multiple sequencing-based TMB technological platforms and panels have to date been reported
to accurately quantify TMB. Francello et al investigated
these platforms and concluded that there is a ‘need for
standardization of TMB quantification and reporting’ in
order for clinical trial TMB results to be compared for
assessment and clarification of their decision-
enabling
potential.29 Not surprisingly, and similarly to scRNA-seq
sequencing platforms, multiple factors including library
generation and sequencing, sample quality, sequencing
depth, and algorithm development may generate significantly different TMB data sets across independent
studies. Currently, two organizations, Friends of Cancer
Research and Quality Assurance Initiative Pathology, are
coordinating and proposing the standardization of TMB
assessments to enable reliable and reproducible patient
results.30
Ring studies for data standardization and lessons learned
from flow cytometry technologies
Flow cytometry is an example of a technology already
known for presenting challenges in data collection and
analysis. This technology remains important for immuno-
oncologists, as it offers the advantage of multiplexing
and quantification, placing it as an indispensable tool for
immune phenotyping of both the blood and tumorous
patient compartments. One of the main observed challenges of flow cytometry has been the generation of
comparable data across studies and across clinical trials
using automated sample analysis. The individual gating
criteria, as well as the signal-
to-
noise ratio of discrete
cellular populations, may have critical impacts on the
variability of data sets even in instances using the same
detection methods, antibody clones, labeling fluorochromes, and sample preparation.31 One of the data
standardization pioneers offering collective ring studies
for academia and industry, as well as cellular reference
samples for controls, is the Association for Cancer Immunotherapy Immunoguiding Program.32
5
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Another major challenge posed by this technology
lies in the identification and quantification of rarer
antigen-specific T cell subsets. A recent comparison of
peptide-MHC multimer-binding T cells from 28 laboratories using different automated gating tools concluded
that the automated gating algorithms tested scored similarly to manual central gating by detecting these cell
populations in the range of 0.0005%–0.0001% of total
lymphocytes.33 None of the tested tools, however, could
be fully automated, as data outputs required user-based
manual decision-making. Still, a careful preselection of
which tools and technologies will be used is paramount,
particularly if clinical trial samples are to be analyzed
using this technology. Standardization of immune phenotyping protocols, including which markers to use and how
to classify immune subsets, together with standardization
of gating strategies are needed for data set integration,
similarly to what has been successfully done, for instance,
by the EuroFlow Consortium in the field of hematologic malignancy diagnosis, prognosis, and therapeutic
response prediction.34
Comparable clinical data elements as precursors to effective
data harmonization
The sharing of comparable data sets has been discussed
above as an important development that will promote
the discovery of robust biomarkers. Several factors
pertaining to study design impair the development of
biomarkers of clinical response, including small sample
sizes and observations reported too early for patients to
exhibit complete or lasting responses to the agent(s)
tested. These issues warrant the sharing of comparable
clinical data sets, in order to assist in the establishment
of well-supported prognostic biomarkers and patterns of
response to IO therapies. It is also crucial that reference
data sets are generated using patient cohorts receiving
non-IO, standard-of-care therapies. As the field of IO still
suffers from deficiencies in the consistency of expected
response criteria among studies, the clinical component
of shared data sets does not always report comparable
clinical features, making it very difficult to correctly pool
and harmonize available data sets.
Clinical response criteria and end points are a highly
debated and evolving area in the field of IO. While investigators continue to favor the use of Response Evaluation
Criteria in Solid Tumors (RECIST),35 they are also considering the other models, including the consensus-based
criteria for response to immunotherapy (iRECIST),36
immune-related response criteria (irRC),37 and immune-
modified RECIST (imRECIST).38 However, others use
measures such as overall survival and 6-month progression-
free survival as a surrogate of success for IO treatments.39 40
Another challenge is that response criteria are cancer
type-
dependent and differ across diseases investigated
(eg, pancreatic cancer vs melanoma and glioblastoma
vs melanoma).41 Two growing SITC-supported international assemblies, the TimIOs initiative and SITCure, are
collectives working at forming long-lasting partnerships
6

with both industry and academia, with the aim of assembling, pooling, and harmonizing gene expression and
clinical data sets from patients receiving immunotherapies during clinical trials.42 Their common goals are to
reveal robust biomarkers of durable patient responses for
the establishment of guidelines for treatment, along with
treatment timelines that ensure that durable, long-lasting
responses can be achieved, while minimizing possible
side effects and the societal and financial burdens associated with unsubstantiated prolongation of treatments.
The sharing of common clinical data elements that can
be used to establish pan-cancer immunotherapy response
criteria is as critically important as any other biomarker-
based feature that can be extracted from harmonized
clinical trial data sets. The solving of this particular
hurdle may require combined meta-analysis and artificial
intelligence approaches, which will only be made possible
if shared clinical data sets are complete and produced to
present comparable common data elements.
In summary, the aforementioned examples underscore
that efficient data set sharing requires careful consideration of the generation of high-quality raw data across
technology platforms early during study or trial design, in
addition to the careful planning and design of harmonizable and sharable data output deliverables. This becomes
especially important when clinical pharmacodynamic
biomarkers are generated to support dose selection, to
provide proof of mechanism, or to identify predictive
response biomarkers. In this context, the generation of
comparable data sets for sharing is paramount for the
eventual development and delivery of more rapid and
efficient treatment opportunities for patients with cancer.
There are vast numbers of studies and trials currently
using multiplexing and multi-omics technologies that are
generating unprecedented volumes of data, all with the
singular hope of identifying simple, robust, and economical biomarkers for CDx development. These biomarkers
will ideally be able to stratify patients and responses to
cancer immunotherapy, but will require intermediate
validation preceding standardization for routine clinical
use.43 This exemplifies the critical need for key stakeholders to subscribe to technological standards that can
be applied across different trials to ascertain that both
biomarker and clinical data outputs will be comparable
and usable for secondary studies, bridging studies, and
meta-analyses that provide the opportunity to statistically
power up initial findings for robust biomarker discovery.
WORKFORCE CHALLENGES
The establishment of a better space for secondary
biomarker data interrogations by making clinical trial
data sets more accessible to the broader research community would require the implementation of a data standards workflow process that would allow data sharing
to be undertaken in a responsible manner. At the same
time, however, the implementation of such a process
could present several additional complex challenges
Cesano A, et al. J Immunother Cancer 2020;8:e001472. doi:10.1136/jitc-2020-001472
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related either to the nature of the stakeholders involved
in providing such data (eg, sponsors and funders, clinical trialists, and regulatory authorities as discussed in the
companion Volume I to this manuscript1), or to the quality
and maintenance of the data committed to sharing via a
central repository. Hence, in order to ensure that data
sharing becomes meaningful, any prospective biomarker
data repository should abide by a data standards workflow
process. For this process to be successful, it should meet
the following two requirements: 1) personnel encompassing a broad range of expertise to enable an end-
to-end workflow in a seamless manner, and 2) data input
must be provided in a manner that is usable and sharable.44 Personnel with a broad range of expertise should
provide the following:
►► Regulatory oversight—Ensure that data deposited for
sharing can be legally and ethically shared. Patient
data should be encrypted and anonymized to eliminate any traceability to the source of origin and any
identifiable data. Moreover, by maintaining continuous contact with regulatory authorities worldwide,
personnel can ensure that core requirements and
practices supporting the responsible sharing of clinical trial data that can be harmonized are met. The
companion Volume I to this manuscript discusses the
protection of patient privacy in greater detail.1
►► Scientific oversight—Confirm the validity of the
parameters measured to enable meaningful interpretation. As described above, in most IO trials, both
cellular and soluble multiplex and multi-omics data
are collected from the blood and tissue samples. The
inputting of such voluminous data sets into a central
repository designed for data sharing can be operationally, logistically, and infrastructurally challenging
but crucially important to foster new discoveries.
►► Bioinformatic
oversight—Ensure that methods
applied to data are comparable or standardized.
Considering that multi-omic data can be derived from
many different sources, one must ensure their comparability among multiple data contributors. In the preceding
Technological challenges section, examples were provided
where, even when common platforms are used in, for
example, flow cytometry, data quality control and analysis
can result in different outputs and interpretation. This
aspect becomes even more challenging when different
assay platforms are used by the end user. For instance,
when enumerating CD8+ T cell content of a tissue, the
tissue preparation conditions, the antibody clones used
for staining, the tissue areas used for enumeration, and
the way that tissues are scored can all lead to completely
different results. Whether the scoring is undertaken in a
quantitative, qualitative, digital, or manual manner can
also cause discordance between different data inputs.
To enable meaningful data usage, the following must be
defined:
►► Type of data to be deposited—By predefining the
minimum amount of sample data that can or should
become available for deposition, one can ensure that
Cesano A, et al. J Immunother Cancer 2020;8:e001472. doi:10.1136/jitc-2020-001472
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comparisons across several trials can be possible. Such
an approach can be guided by already ongoing efforts
to develop standardized biomarkers and assays, as is
the case with the Partnership for Accelerating Cancer
Therapies initiative that aims to provide a systematic
approach to immune and oncology biomarker investigations in clinical trials.4
Comparable data—As already highlighted, the data
generated for deposition must abide by particular
standards of execution. Whether this refers to specific
technologies or to platforms, producers and users
of the data must ensure that similar parameters are
measured in correlative biomarker analyses. The
preceding sections provide further insights as to how
this can be achieved through biospecimen preparation and careful selection of technologies and data
output formats that are akin to other data sets for
downstream harmonization. Only then can cross-trial
data comparisons result in meaningful conclusions.
The availability of treatment and outcome information in integrated data sets from clinical trials,
including data on patient demographics, tumor characteristics, safety, and efficacy, will ensure that benefits
of data sharing are maximized.
Format of the input data—Certain format specifications must accompany all data prepared for input.
Such specifications will enable the swift integration of
new usable data sets into the repository with minimal
need for intervention by data curators. Adherence to
standardized format specifications can also ensure that
respective input data sets are readable and comprehensive and that those containing common data
elements can easily be used for cross-trial comparisons.
Moreover, standardized formats will minimize error
introduction, and thus enable prompt availability of
accurate information to secondary users. It is imperative that such standards and specifications are clearly
disseminated to the data providers for application. An
excellent example can be seen in the cBioPortal for
Cancer Genomics, whereby a standardized bioinformatics workflow was developed, offering continuous
support toward integrative biomarker analysis.45 46
End-user agreements—Similar to other data-sharing
platforms, the terms of use must be agreed on by all
stakeholders. Considering the regulatory sensitivities
imposed by such clinical data sets, there needs to be a
clear mandate and guidance ensuring that all aspects
of the sharing of clinical trial data are undertaken
responsibly and conducted ethically. Such considerations should adopt guidance and recommendations
made by regulatory bodies, either local investigators
and IRBs or national/international regulatory bodies
(eg, the FDA). Moreover, IP associated with the data
provider must not hinder data sharing to the depository (as discussed in the companion Volume I to this
manuscript).
Access to deposited data sets from the European Union
(EU) and the US—In 2018, the EU implemented the
7

Open access
General Data Protection Regulation (GDPR), which
covers the areas of privacy, data protection, and artificial intelligence. The US legislates data privacy differently from the EU and has a variety of federal and state
laws rather than one governing piece of legislation at
the national level. Differences in data sharing and data
distribution models between EU and US databases
are exemplified by the European Genome-Phenome
Archive47 and The Cancer Genome Atlas (TCGA)
data sets.48 The former is overseen by a Data Access
Committee which is responsible for reviewing applications and grants permission for access to potential
users, as defined by the original informed consents.
In contrast, TCGA has both an open-access data set
containing information that does not pose a risk of
patient re-identification as well as a controlled-access
data set that contains information carrying a small risk
of patient re-identification through comparing TCGA
data with information from other data sets.
In summary, in order to ensure that clinical trial data
sharing among the scientific community can be undertaken in a meaningful and responsible manner, a set of
data standards workflow processes must be put into place.
The successful implementation of such processes will
require investment in bringing together appropriately
trained personnel possessing a broad range of relevant
expertise that ensures that all standards associated with
deposition of usable data sets into a centralized repository
are met. Integral to the success of such efforts is the quality
of shared data with common standard data elements to
ensure usability and harmonization for secondary data
interrogation.
Expert personnel training for data management and sharing
Efforts aimed at increasing clinical trial data sharing
will yield poor results if there are too few scientists who
possess the expert knowledge required to generate or
use comparable shared data for secondary analyses. An
adequately sized workforce that is expertly trained in
the operational and technical aspects of data sharing is
thus essential. Within traditional clinical research education, the introduction of mandatory courses and course
modules that specifically educate future investigators and
personnel in all areas of data sharing will be valuable
to ensure an adequately sized workforce. Educational
programs could offer courses on the correct generation of sharable data to quantitative scientists and data
scientists, with key in-class or online modules offered to
medical students and clinicians slated to become or work
closely with trialists. An example of these types of efforts
include a freely accessible ‘Research Data Management
and Sharing’ course already offered by the University of
North Carolina at Chapel Hill and the University of Edinburgh. These types of courses are offered by a number of
online providers, and can be taken for credit or audited,
and thus offer training to trainees from lower-income
or developing countries where financial support may be
limited.49
8

In the future, international bodies that fund the
training of the clinical trial workforce could make
training researchers in data sharing another core component of their initiatives. Governmental funding agencies and foundations that sponsor medical research and
training could also enlarge the scope of their programs to
provide support for training on clinical trial design, with
a focus on planning and implementation of data sharing.
The Wellcome Trust, the National Institutes of Health,
and the Bill and Melinda Gates Foundation are three
examples of funders that impose a mandate for open-
access publication and data sharing from research they
support, and these and other funders could also add even
stronger incentives by supporting data-sharing training
of scholars.32 Furthermore, stakeholders, including large
pharmaceutical companies, could contribute state-
of-
the-art, hands-on training in data sharing, simultaneously
increasing education on the risks associated with data
sharing (ie, IP, regulatory concerns, and patient confidentiality). Other stakeholders, including professional
societies such as SITC, have already held focused workshops on data sharing and have generated summarizing
publications to educate leading industrial and academic
researchers on current viewpoints, expectations, state-of-
the-
art technologies, and exemplary data-
sharing platforms that may be adopted at large to shift modalities for
efficient and standardized data sharing.4 With the shared
goal of creating and fostering a workforce that has the
skills and knowledge to manage the operational and
technical aspects of data sharing, training opportunities
with clear guidelines and incentives can and should be
provided by universities, funders, companies, and professional societies.

SUSTAINABILITY CHALLENGES
For data sharing to be successful, it must be sustainable,
meaning it must be performed using a model where the
costs of maintaining data and data-sharing resources can
be equitably recuperated.32 This challenge is exacerbated
by the fact that the size of some forms of biomarker data
sets are growing rapidly, and in some cases, analysis of
a single sample can generate hundreds of gigabytes of
data.50 Currently, there exist a number of challenges in
the implementation of sustainable data sharing, which we
outline below.
Lack of understanding of data-sharing costs
To date, only a single comprehensive study has been
undertaken to assess the costs of sustainable long-term
data sharing.51 While this study was important, substantially more work in this field is needed to fully understand
data-sharing costs and how, precisely, overall costs are
dependent on predetermined distinct variables of the
data slated for sharing. Any future data-sharing landscape
analysis should also address the following costs, and how
these costs depend on the extent, complexity, and types
of the data and data sets being shared:
Cesano A, et al. J Immunother Cancer 2020;8:e001472. doi:10.1136/jitc-2020-001472
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Table 1 Recommendations to address practical challenges in clinical and biomarker data sharing
Challenge

Recommendation

Infrastructure

Early planning of the interactions and common technology between legal/contractual teams and other
technical project architects/regulators to facilitate mutual agreements and enhance the clarity of informed
consent documents
Educating key medical/technical personnel involved in handling biospecimens to ensure timely collection and
processing of samples
Shared cloud-based storage space with real-time access and supercomputers in academic centers (with
HIPAA compliance and resilience) to allow multi-core computational analyses that can be accessed by multi-
center collaborators

Technology

Selection of standardizable technological platforms for generation of comparable data
Use of supplemental bridging/ring studies to compare data-generating platforms and assess reproducibility
and feasibility of data output harmonization across technologies
Establishment of patterns of patient response profiles to guide future response criteria and trial end points

Workforce

Implementation of a data standards workflow process that allows data sharing to be meaningful and
undertaken in a responsible manner
Availability of personnel encompassing a broad range of expertise to enable an end-to-end workflow, including
well rounded oversight of regulatory, scientific, curation, and bioinformatics aspects of research
Targeted and well-supported training of expert data planning and data management personnel

Sustainability

Creation of data-sharing models where the costs of maintaining data and data-sharing resources can be better
acknowledged and equitably distributed across end users
Better defined cost factors, including required human resources for data sanitization and organization for
comparability, in addition to infrastructure costs for storage and transfer
Bioinformatics tools used to read raw data files must be available long-term, and reliable readability tools
should be maintained and provided in containerized formats
Increased recognition by academic promotion committees to incentivize data sharing
Publishing journals encourage data sharing whenever legally and ethically possible, according to Findable,
Accessible, Interoperable, and Reusable (FAIR) guiding principles 56

HIPAA, Health Insurance Portability and Accountability Act.

►►

►►

►►

Human resource costs, notably including the costs
of responding to incoming data-sharing queries and
requests, and personnel required for the facilitation
of data sharing.
Data sanitization and organization costs associated with making the data usable and comparable
to secondary users, which requires common data
elements for data set harmonization strategies.
Infrastructure costs, including the costs of data storage
and transfer to secondary users.

Unequitable costs of data sharing
Currently, the cost categories outlined above are typically supported by stakeholders or providers generating the data, and few mechanisms exist through
which secondary data users may financially support
the ongoing maintenance of the important data
resources on which their secondary analyses or meta-
studies are based. 32 52 For lasting sustainable data-
sharing models, it is imperative that end-user costs
be distributed more equitably. Funding mechanisms
through which researchers can support data that they
wish to use should be developed. Any such mechanism
would likely need to be overseen by an impartial body
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that would ensure fair and unbiased data access to
secondary users. One benefit of such a body would
be the centralization of data-u se metrics to identify
the features of data sets having the most utility to the
biomedical research community. Importantly, shared
equity of the costs of data access should not become
a barrier to sharing in itself, and non-
p rofit and/
or governmental funding mechanisms to support
access to data for low-resource researchers must be
developed.
‘Dependency hell’ in bioinformatic processing tools
Unlike most forms of clinical trial data, the raw state
of biomarker data is typically an unprocessed, non-
human-
r eadable format that must be subsequently
analyzed and converted to generate features making
downstream analyses possible. Such raw formats
include .bcl, .fastq, and .bam (sequencing); .nd2,
.scn, .liff, and .zvi (imaging); and .fcs (flow cytometry). Historically, bioinformatic tools used to analyze
these data have typically been developed by academic
research labs, and their continued maintenance and
improvement is thus not guaranteed. Additionally,
cascading problems may arise when shared packages
9
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depend on multiple different and incompatible
versions of the same tool, a phenomenon sometimes
called ‘dependency hell’. Useful, sustainable data
sharing for biomarker data requires that compatible versions of tools be available and maintained.53
One approach to address this problematic area is
for the community (including academic journals) to
insist that new data-processing tools be provided in a
containerized format, such as Docker or Si. 54 Furthermore, long-term, centralized storage of containerized
tools should be incentivized and ideally supported
by a governmental funding agency. The embrace of
containers for bioinformatic tools will help prevent
‘dependency hell’ and enable sustainable, useful data
sharing of biomarkers. 55
CONCLUSIONS
The SITC Clinical and Biomarkers Data Sharing
Subcommittee analyzed the current hurdles impeding
efficacy and made recommendations to set standards
for data sharing in IO biomarker and clinical data
sharing. The subcommittee’s recommendations to
address the practical challenges described in this
manuscript are summarized in table 1. Priorities
include early planning of legal interaction networks,
cloud-b ased data-sharing strategies to facilitate data
access and analysis by all core members, ensuring
that projects are managed by personnel with expert
know-how of data standards workflow practices, the
application of appropriate standardizable technologies and unifying protocols that are continuously reassessed during their evolution, and that raw, usable,
and comparable data outputs and storage methods be
in place, with lasting and containerized bioinformatic
algorithms that can continuously be used for their
transformation and analysis.
The field of IO is rich in resources providing the
means to treat cancer. However, there is currently no
centralized database that hosts immuno-g enomic data
from studies involving immune checkpoint blockade,
which would be a valuable resource for the IO community. There is also a need to develop next-g eneration
computational algorithms that allow the extraction of
clinically useful information from the huge amounts
of data being generated using advanced molecular
and cellular tools. These efforts will be critical to
ultimately enable the development of precision IO
treatment. The field of human genomics mapping has
already been challenged by many of these questions
for the last 20 or so years and represents an excellent resource for the IO field for questions of data
management and sharing.
The ultimate goal of this work is to establish a
culture of sharing clinical trial data in which effective incentives for data sharing exist and platforms for
sharing clinical trial data are available, with appropriate data access models and with sufficient total
10

capacity to meet demand. If more than one platform
for data sharing exists, the different platforms need to
be interoperable with adequate financial support for
sharing clinical trial data, and with costs that are fairly
allocated among stakeholders. In this ideal scenario,
appropriate protections will be in place to minimize
the risks of data sharing for all stakeholders and to
minimize sharing disincentives. As a matter of course
for best practices, shared clinical trial data need to
be de-i dentified and modified in response to ongoing
experience and feedback. The subcommittee set out
to help to establish professional standards and to set
expectations for responsible sharing of clinical trial
data, together with requirements to be created by
supporting organizations such as funders, medical
journals, and professional societies (including SITC)
as the best path forward, aiding the culture shift
needed to implement responsible data sharing.
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